Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | CCR1 | P32246 | 10/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775471 | 0.88 | CCR1 (0.44) | CCR1KMT2AKCNH2LMNAP2RY12 | |
| SCHEMBL2776413 | 0.88 | CCR1 (0.46) | CCR1KMT2AKCNH2LMNAP2RY12 | |
| SCHEMBL2774572 | 0.88 | CCR1 (0.47) | CCR1KMT2AKCNH2 | |
| SCHEMBL2777567 | 0.88 | HMOX1 (0.48) | ACACBCCR1KMT2AKCNH2LMNA | |
| SCHEMBL2773529 | 0.88 | ACACB (0.41) | ACACBCCR1KMT2AKCNH2LMNA | |
| SCHEMBL2774403 | 0.87 | KMT2A (0.43) | CCR1KMT2AKCNH2LMNAP2RY12 | |
| SCHEMBL2776489 | 0.86 | LIPE (0.44) | CCR1KMT2AKCNH2LMNAP2RY12 | |
| SCHEMBL2776101 | 0.85 | CCR1 (0.43) | CCR1KMT2AKCNH2LMNATSHR | |
| SCHEMBL2776566 | 0.85 | CCR1 (0.41) | CCR1KMT2AKCNH2LMNATSHR | |
| SCHEMBL2775929 | 0.83 | KMT2A (0.45) | CCR1KMT2AKCNH2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | ACACB 3542/4885CCR1 1428/4885KMT2A 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.